Citations 2
Update from the Long-Term Follow-Up Phase of ReNeu: A Pivotal Phase 2b Trial of Mirdametinib in Adults and Children with Neurofibromatosis Type 1-Associated Symptomatic Plexiform Neurofibroma
Hirbe, A., Shuhaiber, H., Viskochil, D., Sidhu, A., Meade, J., Weintraub, L., Langseth, A., Weber, M., Lokku, A., Hajjar, F., Antony, R., Schiff, D., Raslan, A., Nevel, K., Babovic-Vuksanovic, D., Gershon, T., Hirbe, Angela C. , Shuhaiber, Hans, Viskochil, David , Sidhu, A., Langseth, Abraham J. , Lokku, Armend, Hajjar, Fouad, Babovic‐Vuksanovic, Dusica , Gershon, Timothy R.
Neuropediatrics | April 27, 2026 | Volume: 57 | Issue: No issue available | Pages: No page available
Addressing Skin Adverse Events during Mirdametinib Treatment in Patients with Neurofibromatosis Type 1-Associated Plexiform Neurofibromas: Guidance from Experts on the Management of MEK Inhibitor-Associated Skin AEs
Hirbe, A., Anadkat, M., Boull, C., Nickerson, M., Weber, M., Babovic-Vuksanovic, D., Gershon, T., Hirbe, Angela C. , Anadkat, Milan J. , Boull, Christina , Babovic‐Vuksanovic, Dusica , Gershon, Timothy R.
Neuropediatrics | April 27, 2026 | Volume: 57 | Issue: No issue available | Pages: No page available